Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning

<p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p>...

Full description

Bibliographic Details
Main Authors: Fairchild Paul J, Daley Stephen, Graca Luis, Cobbold Stephen P, Waldmann Herman
Format: Article
Language:English
Published: BMC 2006-04-01
Series:BMC Immunology
Online Access:http://www.biomedcentral.com/1471-2172/7/9
id doaj-88419693dd4c4dc2894d33d125024cec
record_format Article
spelling doaj-88419693dd4c4dc2894d33d125024cec2020-11-25T03:12:12ZengBMCBMC Immunology1471-21722006-04-0171910.1186/1471-2172-7-9Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioningFairchild Paul JDaley StephenGraca LuisCobbold Stephen PWaldmann Herman<p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p> <p>Results</p> <p>We here describe a combined antibody protocol which can achieve long-term engraftment with clinically relevant doses of MHC-mismatched bone marrow, without the need for myelosuppressive drugs. Although not universally applicable in all strains, we achieved reliable engraftment in permissive strains with a two-stage strategy: involving first, treatment with anti-CD8 and anti-CD4 in advance of transplantation; and second, treatment with antibodies targeting CD4, CD8 and CD40L (CD154) at the time of marrow transplantation. Long-term mixed chimerism through co-receptor and co-stimulation blockade facilitated tolerance to donor-type skin grafts, without any evidence of donor-antigen driven regulatory T cells.</p> <p>Conclusion</p> <p>We conclude that antibodies targeting co-receptor and co-stimulatory molecules synergise to enable mixed hematopoietic chimerism and central tolerance, showing that neither cytoreductive conditioning nor 'megadoses' of donor bone marrow are required for donor HSC to engraft in permissive strains.</p> http://www.biomedcentral.com/1471-2172/7/9
collection DOAJ
language English
format Article
sources DOAJ
author Fairchild Paul J
Daley Stephen
Graca Luis
Cobbold Stephen P
Waldmann Herman
spellingShingle Fairchild Paul J
Daley Stephen
Graca Luis
Cobbold Stephen P
Waldmann Herman
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
BMC Immunology
author_facet Fairchild Paul J
Daley Stephen
Graca Luis
Cobbold Stephen P
Waldmann Herman
author_sort Fairchild Paul J
title Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
title_short Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
title_full Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
title_fullStr Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
title_full_unstemmed Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
title_sort co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning
publisher BMC
series BMC Immunology
issn 1471-2172
publishDate 2006-04-01
description <p>Abstract</p> <p>Background</p> <p>A major challenge in the application of marrow transplantation as a route to immunological tolerance of a transplanted organ is to achieve hematopoietic stem cell (HSC) engraftment with minimal myelosuppressive treatments.</p> <p>Results</p> <p>We here describe a combined antibody protocol which can achieve long-term engraftment with clinically relevant doses of MHC-mismatched bone marrow, without the need for myelosuppressive drugs. Although not universally applicable in all strains, we achieved reliable engraftment in permissive strains with a two-stage strategy: involving first, treatment with anti-CD8 and anti-CD4 in advance of transplantation; and second, treatment with antibodies targeting CD4, CD8 and CD40L (CD154) at the time of marrow transplantation. Long-term mixed chimerism through co-receptor and co-stimulation blockade facilitated tolerance to donor-type skin grafts, without any evidence of donor-antigen driven regulatory T cells.</p> <p>Conclusion</p> <p>We conclude that antibodies targeting co-receptor and co-stimulatory molecules synergise to enable mixed hematopoietic chimerism and central tolerance, showing that neither cytoreductive conditioning nor 'megadoses' of donor bone marrow are required for donor HSC to engraft in permissive strains.</p>
url http://www.biomedcentral.com/1471-2172/7/9
work_keys_str_mv AT fairchildpaulj coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning
AT daleystephen coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning
AT gracaluis coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning
AT cobboldstephenp coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning
AT waldmannherman coreceptorandcostimulationblockadeformixedchimerismandtolerancewithoutmyelosuppressiveconditioning
_version_ 1724651043056254976